Transthyretin Amyloidosis (ATTR)
American College of Cardiology (ACC) 2026
Congress Details
28-30 March, 2026 | USA
New Orleans, LA, USA
The materials in this section are intended for UK healthcare professionals and include scientific and educational congress content related to vutrisiran▼. The information contained in these presentations and posters was accurate at the time of presentation. Healthcare professionals should consult the current full Prescribing Information [for the most up-to-date information on indications, dosing, contraindications, warnings, and adverse reactions].
Congress Materials
Presentation Type
Location
Title
Presenter
Jose Gonzalez-Costello
Bellvitge University Hospital, Barcelona, Spain
Presentation Type
Location
Title
Presenter
Robert DiDomenico
Retzky College of Pharmacy, IL, USA
Presentation Type
Location
Title
Presenter
Yasuhiro Hamatani
Brigham and Women's Hospital, MA, USA
Presentation Type
Location
Title
Presenter
Teresa Kauf, PhD
Alnylam Pharmaceuticals, MA, US
Presentation Type
Location
Title
Presenter
Ronald Witteles
Stanford University, CA, USA
Associated Materials
Transthyretin Amyloidosis (ATTR)
Vutrisiran in Transthyretin Amyloidosis: A Pooled Safety Analysis of HELIOS-A and HELIOS-B
JACC: Advances
Transthyretin Amyloidosis (ATTR)
Heart Failure Society of America (HFSA) 2025
Transthyretin Amyloidosis (ATTR)
European ATTR Amyloidosis Meeting (EU-ATTR) 2025
Transthyretin Amyloidosis (ATTR)
European Society of Cardiology (ESC) 2025
Transthyretin Amyloidosis (ATTR)
Realising the therapeutic potential of rapid knockdown of transthyretin via RNA interference in transthyretin amyloidosis
Molecular Therapy Nucleic Acids
Transthyretin Amyloidosis (ATTR)
